Principal Investigator
Mark Pollack, M.D.
Massachusetts General Hospital
- 3 trials
- 1 recruiting now
- 1 compound
Therapeutic focus
- Generalized Anxiety Disorder
- Social Anxiety Disorder
- Post-Traumatic Stress Disorders
Recruiting now (1)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT07489651 | Phase 2 | Recruiting | Luvesilocin (RE104) | Reunion Neuroscience Inc. |
All trials (3)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT07489651 | Phase 2 | Recruiting | Luvesilocin (RE104) | Reunion Neuroscience Inc. |
| NCT02066792 | Phase 0 | Completed | — | Jasper A. Smits |
| NCT00120250 | Phase 4 | Completed | — | Massachusetts General Hospital |
Compounds studied
Trial sites (14)
- Plano, Texas, United States
- Austin, Texas, United States
- Tampa, Florida, United States
- Gilbert, Arizona, United States
- Orem, Utah, United States
- Santa Monica, California, United States
- Atlanta, Georgia, United States
- San Francisco, California, United States
- Decatur, Georgia, United States
- Albuquerque, New Mexico, United States
- Portland, Oregon, United States
- Draper, Utah, United States
- Chicago, Illinois, United States
- Boston, Massachusetts, United States
Investigator and site data mirrored fromClinicalTrials.gov (public domain).